Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors.
Gespeichert in:
| Titel: | Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors. |
|---|---|
| Autoren: | Möhn N; Department of Neurology, Hannover Medical School, Hannover, Germany.; Department of Neurology, University Hospital Bonn, Bonn, Germany., Narten E; Department of Neurology, Hannover Medical School, Hannover, Germany., Duzzi L; Department of Neurology, Hannover Medical School, Hannover, Germany., Thomas J; Department of Neurology, Hannover Medical School, Hannover, Germany., Grote-Levi L; Department of Neurology, Hannover Medical School, Hannover, Germany., Beutel G; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Fröhlich T; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Bollmann BA; Department of Pneumology, Hannover Medical School, Hannover, Germany., Wirth T; Department of Gastroenterology, Hannover Medical School, Hannover, Germany., von Wasielewski I; Skin-Cancer-Center, Hannover Medical School, Hannover, Germany., Gutzmer R; Skin-Cancer-Center, Hannover Medical School, Hannover, Germany.; Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany., Heidel F; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Pessler F; Research Group Biomarkers for Infectious Diseases, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture of Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany., Zobl W; Research Group Biomarkers for Infectious Diseases, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture of Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany., Schuchardt S; Department of Bio- and Environmental Analytics, Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany., Ivanyi P; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Nay S; Department of Neurology, Hannover Medical School, Hannover, Germany., Skripuletz T; Department of Neurology, Hannover Medical School, Hannover, Germany. |
| Quelle: | Oncoimmunology [Oncoimmunology] 2025 Dec; Vol. 14 (1), pp. 2547271. Date of Electronic Publication: 2025 Aug 16. |
| Publikationsart: | Journal Article |
| Sprache: | English |
| Info zur Zeitschrift: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015- : Philadelphia, PA : Taylor & Francis Original Publication: Austin, TX : Landes Bioscience |
| MeSH-Schlagworte: | Immune Checkpoint Inhibitors*/adverse effects , Triglycerides*/blood , Neoplasms*/drug therapy , Neoplasms*/immunology , Neoplasms*/blood , Drug-Related Side Effects and Adverse Reactions*/etiology , Drug-Related Side Effects and Adverse Reactions*/blood, Humans ; Female ; Male ; Middle Aged ; Aged ; Prospective Studies ; Metabolomics/methods ; Risk Factors ; Aged, 80 and over |
| Abstract: | Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by enhancing anti-tumor immune responses, yet their use can lead to immune-related adverse events (irAE), including neurological complications. Despite their clinical relevance, predictive biomarkers for irAE remain scarce, and early identification of at-risk patients is a major unmet need. In this prospective study, 200 patients undergoing ICI therapy were enrolled, of whom 59 underwent longitudinal metabolomic profiling at baseline, three months, and six months. Thirty-two patients who developed irAE were compared to 27 age- and sex-matched individuals without irAE. Multivariate analyses, including Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA), revealed distinct metabolomic signatures differentiating the two groups. Notably, baseline levels of triglyceride 20:0_34:1 were significantly lower in irAE(+) patients. In female patients, additional triglyceride species-20:1_34:2, 20:2_34:2, and 20:2_34:3-were also reduced prior to therapy and showed increases within three months of ICI initiation. These findings suggest that specific triglyceride species may serve as early biomarkers for irAE risk, particularly in female patients. The observed dynamic changes point to a potential link between lipid metabolism and immune-related toxicity, supporting the integration of metabolomic profiling into future strategies for risk stratification and personalized monitoring in cancer immunotherapy. |
| References: | Front Immunol. 2023 Apr 26;14:1140677. (PMID: 37180131) MedGenMed. 2003 Aug 07;5(3):20. (PMID: 14600656) Ann Ist Super Sanita. 2016 Apr-Jun;52(2):205-12. (PMID: 27364395) NPJ Precis Oncol. 2023 May 12;7(1):41. (PMID: 37173424) Front Immunol. 2022 Apr 26;13:779691. (PMID: 35558065) Rheum Dis Clin North Am. 2024 May;50(2):281-290. (PMID: 38670726) J Clin Lab Anal. 2019 Sep;33(7):e22929. (PMID: 31350776) Mediators Inflamm. 2021 Jan 5;2021:6634532. (PMID: 33505215) Front Immunol. 2022 Nov 25;13:1032221. (PMID: 36505471) J Immunother Cancer. 2021 Mar;9(3):. (PMID: 33789879) Int Immunopharmacol. 2024 Jan 25;127:111412. (PMID: 38160567) Oncotarget. 2017 Dec 14;8(69):114268-114280. (PMID: 29371985) J Natl Cancer Inst. 2021 Oct 1;113(10):1396-1404. (PMID: 33705549) J Clin Med. 2019 Oct 24;8(11):. (PMID: 31653079) Expert Rev Anticancer Ther. 2022 Aug;22(8):861-874. (PMID: 35786142) Cancer Med. 2023 Apr;12(8):9373-9383. (PMID: 36794673) Pulmonology. 2024 Jul-Aug;30(4):352-361. (PMID: 35414494) Int J Mol Sci. 2019 Jan 15;20(2):. (PMID: 30650575) Dtsch Arztebl Int. 2019 Feb 22;116(8):119-126. (PMID: 30940340) Thorac Cancer. 2020 Sep;11(9):2406-2430. (PMID: 32643323) Expert Opin Drug Saf. 2020 Apr;19(4):479-488. (PMID: 32126176) JAMA Oncol. 2022 Dec 1;8(12):1794-1801. (PMID: 36301521) Cancers (Basel). 2023 Mar 06;15(5):. (PMID: 36900420) Cancer Immunol Immunother. 2020 Sep;69(9):1813-1822. (PMID: 32350592) Expert Rev Clin Pharmacol. 2023 May;16(5):423-434. (PMID: 37144360) Front Med (Lausanne). 2019 May 29;6:119. (PMID: 31192215) Cells. 2021 May 06;10(5):. (PMID: 34066349) Nat Rev Dis Primers. 2020 May 7;6(1):38. (PMID: 32382051) Oncologist. 2019 Aug;24(8):1128-1136. (PMID: 31015312) J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34172516) |
| Contributed Indexing: | Keywords: Checkpoint inhibitors; biomarker; immune-related adverse events; metabolomics; neurotoxicity |
| Substance Nomenclature: | 0 (Immune Checkpoint Inhibitors) 0 (Triglycerides) |
| Entry Date(s): | Date Created: 20250816 Date Completed: 20250826 Latest Revision: 20250826 |
| Update Code: | 20250826 |
| PubMed Central ID: | PMC12360195 |
| DOI: | 10.1080/2162402X.2025.2547271 |
| PMID: | 40817886 |
| Datenbank: | MEDLINE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by enhancing anti-tumor immune responses, yet their use can lead to immune-related adverse events (irAE), including neurological complications. Despite their clinical relevance, predictive biomarkers for irAE remain scarce, and early identification of at-risk patients is a major unmet need. In this prospective study, 200 patients undergoing ICI therapy were enrolled, of whom 59 underwent longitudinal metabolomic profiling at baseline, three months, and six months. Thirty-two patients who developed irAE were compared to 27 age- and sex-matched individuals without irAE. Multivariate analyses, including Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA), revealed distinct metabolomic signatures differentiating the two groups. Notably, baseline levels of triglyceride 20:0_34:1 were significantly lower in irAE(+) patients. In female patients, additional triglyceride species-20:1_34:2, 20:2_34:2, and 20:2_34:3-were also reduced prior to therapy and showed increases within three months of ICI initiation. These findings suggest that specific triglyceride species may serve as early biomarkers for irAE risk, particularly in female patients. The observed dynamic changes point to a potential link between lipid metabolism and immune-related toxicity, supporting the integration of metabolomic profiling into future strategies for risk stratification and personalized monitoring in cancer immunotherapy. |
|---|---|
| ISSN: | 2162-402X |
| DOI: | 10.1080/2162402X.2025.2547271 |